| |
Introduction:
As
regards oncology nowadays the statutory health insurance agencies
can only fulfill their tasks predetermined by the legislator to
a limited extent. In the light of secured knowledge this at least
fully applies to Sect.12 of the code of social law comprising social
security services (SGB V.) as far as the legal situation in respect
of the stipulation of economic efficiency is concerned .
The
respective text of the law reads as follows:
The
benefits must be sufficient, adequate and economic, they shall not
exceed the necessary limit. Benefits which are unnecessary or inefficient
cannot be claimed by the insured, shall not be provided by the grantor
of benefits and not be granted by the health insurance agencies.
|
|
The
statistician of the German Centre for Cancer Research of Heidelberg
(1) already revealed in his publication of 1990 that the statutory
health insurance agencies presumably illegally provide benefits
in kinds for matter-of-routine therapies with cytotoxics (chemotherapy).The
reason : The said therapy methods do not ascribed any life-prolonging
effects. Moreover,the dramatic deterioration of the quality of life
substantially affects the remaining life span of cancer patients.
It can be seen from the chart (Fig 1) which shows recently published
statistics from the German Centre for Cancer Research in Heidelberg.
(DKFZ) that up to now the situation has not changed.
According to the disillusioning results from Heidelberg, chemotherapy
has an effect with only 5% of the patients, provided it is combined
with resection and radiation.This is because most cancer patients
present late and are therefore not suitable for surgical resection
of their tumors.
About 400,000 patients per annum still die from the aftereffects
of the mentioned useless attempts of treatment (2) or of the cancer
per se. The German Cancer Congress estimated the cost expenditure
for treating cancer patients at DM 125,000 to DM 1.5 Million per
patient, mind you, for often ineffective methods of treatment.
|
| |
 |
|
THE
THERAPIES BY WHICH CANCER IS CURED |
| |
|
|
 |
|
| |
Chart
1:chart by the German centre for Cancer Research,Heidelberg
|
|
|
|
|
Even
the most recent new combinations of chemotherapies and conventional
therapies that may be disguised as " scientific studies"
and are newly promoted by certain groups of experts which are charged
at the expense of the insurance agencies, fail to change the factual
situation. They all the more oppose the stipulations of Sect.70
of the code of social law comprising the social security services
(STGB V.) concerning quality, humaneness and economic efficiency.
The insuree's money to an amount of two-digit billions-according
to estimates - are may therefore be fruitlessly spent.
The alleged " scientific character" of the mentioned unallowed
studies at the expense of the health insurer fails to change this;
the same applies to neoplasms, such as those for " therapy
optimisation " (3) They merely and unnecessarily diminish the
people's faith in the otherwise time-honored principles of classical
medicine.
|
|
|
 |
|
|
Against
this background it is not only the responsibility of the social
security institutions, but also the responsibility of the
other groups of medical experts, especially after the oncologically
oriented groups of experts have started to shun their responsibility.
The damage caused to the overall economy at the expense of
the joint society of health insurance has already reached
substantial proportions and can be easily estimated (cf. above)
Mainly
responsible are the doctors in the medical service of the
health insurances (MDK). It is their duty to present the scientific
knowledge which has been ascertained already since 1990(1)
from a factual point of view and in accordance with the stipulations
of Sect. 275 SGB V . This means : they are liable to translate
the said knowledge into common language that is comprehensible
by the laymen employed with the health insurances.
By doing so, the medical progress that are reached can then
be integrated into the social security too, as stipulated
by Sects 63 to 66, SGBV., para.3. And only in this way the
insured can be prevented from further damage.
In practice, the necessity. remains to translate the seemingly
twisted, but by now valid scientific knowledge and facts in
a form that is comprehensible by the layman and to realize
it in therapy. The aim: Not only the responsible people at
the health insurance but also those directly affected , namely
the insured themselves should be enabled to analyse the factual
situation. It is therefore one of the objective of the following
explanations to present as a working basis an evaluation of
the scientifically determined facts pertaining to the field
of oncoimmunology in a form that is comprehensible by the
medical layman.
Another objective is to provide a practical working assistance
for the medical services, health authorities and also authorities
providing financial aid to patients.
In practice, these explanations serve the purpose of acquainting
the patients, i. e. the persons involved and their relatives
with the complex scientific facts relating to oncoimmunology
by means of a generally comprehensible presentation.
|
|
|
|
|
|
|
What
are Cytokines?
In
classical medicine, the field of immunotherapy has been established
many decades ago.
The immune system and hence the individual
endogenous defenses can either be activated directly, i.e.
specifically targeted, or indirectly, i.e. unspecifically
targeted, a difference which will be explained later on.
The success of whatsoever
type of defenses , be it a specific or an unspecific one ,
is due to signal transduction. This means the transduction
of information while the defenses mechanism is working in
the body namely between the immunoactive cells of the blood
and the tissular cells of the body.
Targeted
Defense:
Cytokines
are the signal and messenger substances that are used by the
immune system for a targeted defense-they are divided into
interferons (IFN) and interleukins (IL) according to their
origin and task and are readily referred to as the "
language of the immune system . " Their components are
specific to the individual; comparable to his fingerprints,
i.e. therefore also in the human species they are characteristic
for each individual and might be compared to the letters of
the alphabets. When the endogenous defenses are activated,
whole cascades of cytokines are grouped into " precise
" words and these words are then grouped into comprehensive
" sentences " .
The effector cells : the leucocytes and the lymphocytes, communicate
among each other and with the tissular cells by means of the
different cytokine cascades .Each single step towards self-healing
,which is similar to the language processes, is individually
determined by the different word orders (different combinations
of cytokine cascades ). It is in this manner that bacteria,
fungi and viruses,which are unnoticeably inhaled into the
lungs with each breath , can then be repelled and destroyed
without us knowing it.
Cytokines
as medicine
It's
a natural desire therefore, to try to make use these natural
antibodies as pharmaceutical preparations (4) in cancer therapy.
Synthesized through genetic engineering or from the use of
foreign blood, the retorts-IFN and - IL ( recombinant cytokines
), however, have not met with high expectations. They have
only one thing in common: an excessive number of dangerous
and potentially life-endangering side-effects as well as high
pharmacy selling prices.
The prepared cytokines lack the specific therapeutic, i.e.
the targeted effects. Their effects are exclusively limited
to an non-specific effect, i.e. to the untargeted immunostimulation
(4) as is sufficiently known for treatments with foreign proteins.
Hence, the use of targeted and specific immunodefense methods-particularly
without the dangerous side-effects-have been mainly restricted
to the use of autologous target cytokines (Own Blood Cytokines
) . It is for the reasons that the different types of autologous
cytokine therapies
(Own
Blood Cytokines )
as a medical service had become a fixed part of the scale
of medical fees (GOÄ) for many decades.
|
|
|
|
|
|
|
Application
in practice
The
well-founded scientific fundamental knowledge, and its theraupeutic
applications in practice are often two different pairs of
shoes. This experience can also be obtained from evaluating
the therapeutic treatment with recombinant cytokines. Even
today the specific effects of the autologous target cytokines
( Own Blood Cytokine ) is often equated to the non-specific
effects of recombinant cytokines , which leads to considerable
false estimations and indications being made.
Not even certain groups of medical experts are above these
false estimations . And often it is considered a "more
valuable asset " to carry out therapeutic studies on
recombinant cytokines rather than take into account the quality
of life or the length of survival of the patient that is suffering
from cancer.
This , again, makes it more difficult for the medical services
of the health insurance agencies to do the tasks assigned
to them by the legislators ; especially in cases where a decision
on the financing of recombinant cytokine studies must be made
(cf. Sect. 66, SGB V.,chapter 10).
Often
, real conflicts of interests arise not only at the expense
of the patients but at the expense of the health insurance agencies
as well. This situation is still aggravated if the respective
professional organisations (and competent Medical Boards ) are
biased .
Natural
tumor defense
It
is a well-known fact that many natural environmental influences
contribute to the formation of cancer, and that the endogenous
immune system repells them quite naturally . A typical example
of that is the reddening of the skin after a sunbum:
The skin reddens because of thermic exposure and is soothed
in the shade and then becomes pale . Only hours later the
skin reddens, i. e. shows sunburn. By that time only the endogenous
immune system will have recognized the damages to the hereditary
material of the skin cells caused by the solar irradiation
(chromosome aberrations / chromosome breaks) and it commences
to repair those damages by means of an inflammation (reddening
) (the so-called repair mechanisms.).
Only after all potential cancer cells have been repaired does
this inflammation subside . The inflammation is an important
and necessary part of the immune defense mechanism, including
the endogenous defense system that fights against cancer cells
(healing inflammation).
If the skin damage caused by exposure to the sun has been
too intense and is irreparable , the skin is desquamated and
a bullous exanthema is formed (vesication) and the skin is
renewed in total.
The above mechanisms of biological cancer defense and also
similar mechanisms are carried out in the human body
many thousands of times every day.
|
|
|
|
|
|
|
Cancer
cell repair
Millions
of body cells ae renewed every day by means of cell divisions
. During this process eucaryotic organic and tissular cells
as well as cells with modified hereditary material , i.e.
potential cancer cells, are formed. The cancer cells, recognized
as faulty cellular structures, are easily identified by the
immmocompetent cells of the defense system . By means of the
so-called repair mechanisms, the immune system of the human
body repairs the body cells that are recognized as faulty
and repairs the hereditary material in a process similar to
the one observed with sunbrn.
During the said process, the B-Iymphocytes-comparable to scout
cells tansform themselves into plasma cells , which in turn
produce antibodies that mark the tumor cells and with their
aid repair or destroy them.
Through a well- balanced interaction of the different T-cell
subpopulations ; the helper cells and suppressor cells , the
remaining T-cells are now activated . If need be , natural
killer cells (NK)destroy the tumor cells by means of chemical
substances, called perforines, which causes the mortification
of the cells .
Fig.1:
Signal transduction in vitro : nutural killer cells have occupied
the cell membrane of the tumor cell. Cireular defects in the
cell membrane (arrow a ), which look as if they have been
perforated, after digestive impact of the perforine synthesis
at the contact point NK cell : tumor cell membrane arrow b
: NK cell in action(enlargement:screen electronic microscope).
Macrophages
swallow the fragments of the destroyed cancer cells (phagocytosis
). Smaller fragments are digested, bigger ones are transported
away and are catabolized e.g. through the liver.
Causes
of cancer formation
For
the 400,000 cancer patients in Germany each year, the described
biological cancer defense mechanisms fail to function . What
are the causes for this failure?
For may decades the opinion prevailed that a tumor might only
be formed in a weakened or faulty immune system. Scientifically,
it was postulated that chronic viral infections often coincided
with the formantion of cancer.
The above hypothesis was even confirmed by animal tests.
Today we know that the mentioned theory regarding the formation
of cancer only applies in rare cases.
The same can be said of the doubtful results
obtained by animal testing . Nowadays, genetic manipulation
has made it possible for any animal testing to be successful
because the required conditions for testing can be artificially
created; even though this may go against the fundamental Laws
of Nature. Merely, adequate animals have to be produced first
(e.g. transgenetic mice )and virtually everything is confirmed
" scientifically" . These animals are bred to have
a deficient immune system, so that human tumor cells can be
transplanted into them without being immunologically rejected
by these specially bred animals.
In nature and in practice this is , however , completely different.
Everybody who has experience in dealing with cancer patients
will know that if the cancer diagnosis is confirmed; the news
usually strikes the patient like lightning. Usually, the very
people who are affected are those who " have never been
ill throughout their lives " This practical experience
too, may induced an internal reorientation of his endogenous
defense system .I t is known today as fundamental knowledge
in classical medicine that only in rare cases, do the
weakened endogenous defences cause the formation of cancer.
|
|
|
|
|
|
|
Enveloping
of cancer cells
It
is scientifically well-founded that the enveloping of the
cancer cells as such is the reason for the formation of cancer
(6). The cancer cells owe their ability to survive in an intact
immune system due to this protection in order that they may
remain unidentifiable (Tab 2,A)
.
Already
in the 70s our working group had pointed out the said enveloping
of tumor cells and recognition mechanisms (7-9). Our findings
were confirmed by other scientists, e.g. the German Centre
for Cancer Research, Heidelberg, in 1992, i.e. at a time (6)
when our working group had for many years already experienced
therapeutic successes based on the said findings.
Tumor cells produce so-called surface markers, such as e.g.
CD44v (6) for their own protection which are comparable to
a magical cap. " Enveloping " is the scientific
term for this process.
The surfaces are the same as those produced by lymphocytes
.In the blood cancer cells incorporate into the phalanx of
lymphocytes, pretend to be them and hence remain unidentified.
Certainly, this is not the only protection against indentificatoin
and defense. Recent examinations confirmed that tumor cells
also carry protective substances on their surfaces which are
similar to hormones ,e.g. the hormone B-HCG.
Thus ,the cancer cells achieve additional protection against
immunological detection, similarly to the ovum protecting
itself from being discharged from the uterus.
This is the reason why the tumor cells can multiply unimpededly,
At a very early stage they spread via the bloodstream and
the lymphatics ( " haematogenous " and " lymphogenous"
metastatic spread).
|
|
|
|
|
|
|
Tumor
stem cells
Long
before the first clinical hints at a tumor disease and diagnosis
thereof, tumor mestastases have already spread. This was confirmed
by the fundamental examination results obtained by the Riethmuller
working group, Munich, (10-17).L
By means of an early metastatic spread of individual tumor
cells into the bone marrow the metastatic cells adapt to the
sterm cells of the bone marrow and - as described above-can
no longer be differentiated from the other stem cells of the
bone marrow by the defense of the immune system.
In accordance with Riethmuller (18) we talk of tumor stem
cells in such cases.
Strategically
important spot
The
bone marrow is the site of great strategic importance for
the tumor stem cells . Similar to blood cells which are produced
by the stem cells of bone marrow and are then washed out via
the bloodstream or the lymphatics, tumor cells are equally
produced by the tumor stem cells in the bone marrow and are
washed our via the bloodstream or the lymphatics, as they
metastasize.
This also is the reason why the surgical resection of cancer
only leads to a restitutio ad integrum, i.e. recovery, if
it was carried out at a very early stage prior to the clandestine
formation of metastases.
However , if a tumor is already causing suffering in the patient
or if it is easily visible and hence has been discovered and
resected only as a result thereof ; usually millions of tumor
cells are already circulating in the bloodstream and the lymphatics
of the patient.
Early
cancer diagnosis and early resection:
Though
surgical resection results in a reduction of the tumor mass,
the metastatic spread has already taken place and can be cured
in only 5% of all tumor cases with the conventional therapies;
and also only in combination with radiation and chemotherapy.
With the remaining 95% of all tumor cases (table 1) it is
only a matter of time before the relapse of the tumor manifests
itself anew because of the lymphogenous and haematogenous
metastatic spread that have already occurred in the patient.
This also explains why the number of new cancer cases and
its mortality rate in Germany have remained almost equal over
the years despite of all the costly and complicated therapeutic
measures that are undertaken by the patient ; besides also
expesriencing a poorer quality of life by the patient. Against
this backdrop, early cancer diagnosis deserves the utmost
priority.
|
|
|
|
|
|
|
Way
out :Immunotherapy
Not
only in the case of gastrointestinal tumors, i.e. tumors of
the gastrointestinal tract (2) and the different forms of
the mammary carcinomas (breast cancers ) (19), have conventional
chemotherapy regimes so far failed to cure the patient but
there are even reports of deaths as a result of therapy in
some cases.
In the case of the other types of tumors (1) it was just as
little possible to prolong the life by chemotherapy .
The only exception are the different kinds of leukaemia ,
tumors of the testicles and small-cell bronchial carcinoma.
But here , too, chemotherapy does not fundamentally or in
all cases mean a cure.
Hence, today only immunotherapy remains to give the hope for
a reasonable chance of a cure for the patient's cancer. For
many years, it was used as an adjuvant therapy, i.e. concomitantly
used in classical medicine ; this natural form of treatment
is used as a defense against tumors and have been gaining
more and more importance and significance in the recent years.
With regards to immunotherapy, we differentiate between two
important , completely different treatment principles : the
specific and the non-specific immunotherapy.
Non-specific Immunotherapy : An
example thereof , is the treatment with foreign proteins such
as misteltoe or its lectin , and similarly the cytokine preparations
belong to this group.
In non-specific immunotherapy,
the immunosystem is activated (only) in general . The effect
is limited to the improvernent of the general defense situation
unless when too high doses are used that result in side-effects.
There are no specific targets of the non-specific immunodefense
mechanisms.
Specific immunotherapy : In
this class, only the very complicated ASI-therapy according
to Schirrmacher (20), which is only restricted to certain
kinds of tumors and the therapy using autologous target cytokines
( Own Blood Cytokine ) are known.
The specific immunotherapy activates the immune system in
a targeted manner against the tumor .
In the case of the specific immunotherapy too, the therapeutic
effect is divided into two steps :
The first step comprises the specific targeted inflammation
at the tumor and its metastases :
The cellular correlate for this is the activation of the B-lymphocytes
to become plasma cells which , in turn , recognize the tumor
cells as an antigen and make them identifiable with the aid
of antibodies which they deposit on the surface of the tumor
cells, i.e. determination as an antigen; thereby the defense
function of the T-cell line is stimulated (cf . above
).
The second step is the direct destruction of the tumor :
The cellular correlate for this is the control through helper
and suppressor cells and the activation of the natural killer
cells (NK), followed by the mortification of the tumor cells
and the removal through macrophages . These are specific to
the individual and are highly specific processes whose duration
is determined by different factors and co-factors.(22).
|
|
|
|
|
|
|
|
Lab
technology :
Already
in the early phases of tumor disease about 1 million
tumor cells circulate in the blood of the cancer patient
, i.e. about 2,000 tumor cells calculated per 50 ml
(10-17) of peripheral blood . This is exactly the amount
of blood or the number of tumor cells which are required
for the relevant tumor cell-targeting in-vitro.
While in vivo, i.e. in the body of the cancer patient,
the tumor cells are protected form immunological recognition
via enveloping (Table 2 A ) . But in-vitro , it is possible
on the other hand , to deprive the tumor cells of this
enveloping . In 1978 we had already morphologically
demonstrated (7,8) that tumor cells and macrophages
which are drawn with the blood of the patient, will
give up their enveloping for brief moments, e.g. during
the cell division phase. During this mitosis phase,
the tumor cell is not protected because its outer cell
membrane, nucleus and nuclear membrane are being restructured
. Now they quickly become prey to the leucocyte and
lymphocyte recognition.
Before long, leucoctes migrate to the place of cell
division within in the cell culture of the patient's
nucleated cells using the patient's own serum; and occupy
the entire surface of the tumor cell (Fig. 2). In this
situation, signal-transduction (targeting ) between
the leucocytes and tumors takes place unhindered. As
with any other immune defense processes, the entire
immunological transduction cascade is now initiated
(cf. above ); first, antibodies are produced by plasma
cells ; followed by the controlled activation of killer
cells (NK); and finally the tidying-up activities of
the macrophages (phagocytosis ) occur.
|
|
|
|
Fig
2: signal transduction in vitro:at the lower edge of the picture
there are two tumor cells in rest plase .In the center of
the picture a tumor cell in mitosis is obvious whose
surface is occupied by a plurality of leucocytes . Enlargement:lens
16, phase contrast.
From
Fig. 3 the signal-transduction processes are more obvious. The different
B-and T-lymphocytes, killer cells and macrophages communicate by
means of pseudopodal appendices.
When seen on the scanning electron microscope ( Fig. 1) the result
becomes clear : a tumor cell is occupied by several killer cells,
the tumor cell membrane is punctually destroyed 8 cf. arrows, Fig.
3). In the lab this takes place entirely by natural means i.e. just
as well as with the biololgical tumor defense
.
|
|
|
 |
|
|
To
contral the signal transduction
However,
this form of signal transduction depends on the speed of the
spontaneous cell division of the tumor cells in vitro , which
often takes place very slowly . Therefore , it was necessary
to try to expedite and intensify the signal transduction
process between the leucocytes and tumor cells in the cell
culture. To optimize this effect in the laboratory, demasking
is done mechanically, and not chemically ( Fig. 2B).
|
|
|
|
|
The
great advantage
This
has the advantage that all tumor cells may be simultaneously subjected
to the same autologous signal transduction processes during a short
and precisely controlled period of time. When the now demasked tumor
cells are reincubated along with the autologous leucocytes, spontaneous
signal tansduction the takes place in the laboratory in the same
manner as descrjbed above ( Table 2 C).
As a result of this (mechanical separation of tumor enveloping ),
the addition of foreign substances necessary with other methods
becomes redundant. This technique ensures that only endogenous (autologous
) materials are used (Table 2 D), which is the sole prerequisite
for causing a specific immunostimulation.
|
|
|
|
|
|
|
|
" Branch office " of the immunosystem , the lab
What
is blocked in the body of the cancer patient by the biological immuno-defense
of tumor cells , may be overcomed in the laboratory with the method
that is described above ( Table 2 ).
Figuratively speaking, the laboratory is comparable to a small branch
office of the immune system where it is possible to reproduce the
natural defense steps of the immune system in a manner just as natural
as in the body of a healthy person. In this context the yield of
antitumor-specific cytokines is considerable ( Table
2 D ) and depends on different factors and co- factors (22).
Table 3 shows what amounts of target cytokines can be made available
by the above described laboratory technique. In particular, the
autologous cytokines TNF and sIL2-R have established themselves
as clinically effective and provened to have particularly clinical
effects.
|
|
|
|
 |
|
|
|
Table
3 (4 pictures in toto ):cytokine measuring values (IL-2,IL-3,IL-6,TNF
)hatched: prior to the signal transduction in vitro; black : after
the signal transduction in vitro. State after 72 hours of incubation
in - vitro by an example of 14 patients in toto.
|
|
|
|
Remarks
: the tables demonstrate the individual activation of the autologous
cytokiones with respect to time , depending on the different factors
and co-factors.
|
|
|
|
|
|
Mind
you, these autologous cytokines are to be distinguished from
the exogenous, the heterologous or homologous cytokine preparations
, both with regards to their actions as well as their side
effects (cf.chapter immunotherapy).
Of a superior mature as far as their therapeutic effect is
concerned, the autologous target cytokines ( Own Blood Cytokine
) are free from undesired side effects. Their specific effectiveness
only becomes relevant directly at the tumor.
Course of therapy:
These
specific effects on the tumor also becomes quite clear during
the course of therapy. There are no local reactions at the
site where the autologous target cytokines ( Own Blood Cytokine)
have been injected .A reddening , i.e. an inflammation, which
is caused by an inflammatory infiltrate, only establishes
itself at the site of tumor and its metastases.
In the first step, this initially becomes apparent in the
form of a slight swelling at the site of the tumor which is
dependant on the different factors, and which later changes
smoothly to the destruction of the tumor in the second step.
Skin metastases, for instance, become initially infiltrated
and than become reddened; just as in the case of any other
inflammation. This positive effect should by no means be confused
with a " local relapse " of the tumor or with a
progression of the tumor . It is due to this inflammation
that a reduction of the tumor mass or a disintegration of
the inflammatory infiltration with an outward emptying of
the tumor is seen.
This spontaneous discharge is a therapeutic part of naturopathy
which has been known for centuries (e.g. scarification, cupping
glasses ) and which in this case takes place sporitaneously
during the therapy with autologous target cytokines ( Own
Blood Cytokine).
The success of the treatment is naturally measured by the
above described effect on the tumor or its metastases and
subsequently by their reduction.
|
|
|
|
|
|
|
Often
very late
Our
experience has shown that unfortunately patients too often
come for this treatment only at a very late stage of their
disease; namely when they have been previously treated for
months, in part even for years with chemotherapy , which later
tumed out to be completely useless.
In
such cases, the immune system has been previously weakened
during such therapies , and often " miracles " are
expected now.
Fortunately, it is not a " miracle " because even
at such a late stage that the hope for a healing effect are
fulfilled by the therapy with autologous target cytokines(
Own Blood Cytokine) (24).
Therapeutical
successes:
It
is surprising that also in such grave and far advanced cases
that the autologous target cytokines ( Own Blood Cytokine)
do not fail to be effective in treating the patient's cancer.
Fig.4 shows the cerebral metastasis of an unknown primary
tumor with extensive oedema formation after chemotherapy and
radiation treatment were not successful.
At this point in time the patient clearly suffered from paralytic
symptoms, the tumor had already broken through the falx cerebri.
Six months later already, in the course of the second autologous
target cytokines ( Own Blood Cytokine) series the tumor has
largely receded (Fig 4b).
In 1992 already, the gynaegological clinic of the university
Wurzbarg could confirm the following : that in about 50% of
all cases there is a partial remission, a standstill (no change
) or at least a delay in the tumor growth (slow progress )
even if the initial diagnosis was infaust (23). Such positive
therapeutic results cannot be obtained with any other treatment
measure known today .
This also applies to the case of a 50 year old patient with
osteosarcoma and multiple metastases to the lung (Fig. 5a)
. Eight months of therapy with autologous target cytokines
( Own Blood Cytokine) reduced the metastases by about 60%
(Fig . 5b), a therapeutical success which could not be achieved
by any other therapy, not even by chemotherapy which had been
previously tried.
|
|
|
|
|
 |
|
|
|
Fig.
5a : multiple metastases of an osteosarcome of the lung .
|
|
|
|
Fig
4a : cercbral metastasis of an unknown primtary tumor , simultaneously
there is a marked cerebral oedema farmation. The namor has broken
through the falx cerabrt.
|
|
|
|
Fig.
4b : 6 months of therapy with autologous target cytokines. ( Own
Blood Cytokine)
The
tumor has largely receded .
|
 |
|
|
Fig
5b: 8 months of therapy with autologous target cytokines ( Own Blood
Cytokine)
:
reduction of metestases by about 60 % .
|
|
|
|
|
|
The
" special oncology " phenomenon
Oncologists
do not always wish to fundamentally acknowledge or admit the
therapeutic successes of others against the backdrop of their
own unsuccessful attempts at treatment.
The Artzbrief of the LVA Klinik Heidelberg (Fig. 5c) shows
that such therapeutic successes are even deliberately ignored
. The Heidelberg oncologists did not even shrink from stating
the facts in an altered way .
It is stated in this connection that :
" despite chemotherapy a no-change situation is determined....
" ,
which is the reason why this patient was still quickly operated
before a complete healing had taken place with autologous
target cytokines ( Own Blood Cytokine) .
What is particularly tragic in this examplary case is that
the patient did not survive the aftereffects of the said resection
(Fig. 5d ). There are numerous documents as proof of such
and similar examples for the " special oncology phenomenon"
.
|
|
|
|
THORAXKLINIK
der
LVA Baden
HEIDELBERG-ROHRBACH
|
|
|
|
|
Case
history and OP-indication :
In
the case of Mrs. ...a no-change situation of he lung
metastases was determined after the above described development
of the disease and renewed chemotherapy. It appeared
that the centrally threatening metastatic spread along with the
corresponding complication phenomena, such as central obstruction
of the respiratory tract and erosion bleeding from the central vessels,
could only be overcome by operative intervention.
|
|
|
|
Fig.
5b : State after the operation of the patient who did not survive
the aftereffects of the operation . |
|
Representative treatment successes
The
Institute for Immunology and Cytobiology in Munich has compiled
and briefly documented one hundred representative successful
treated cases of different types of tumor diseases ; by examples
of the so-called tumor patients that have been cured by autologous
target cytokines ( Own Blood Cytokine) therapy (24).
With this , we have proven that even at advanced tumor stages
and also for most types of tumor diseases that an anti-tumor
effect by autologous target cytokines ( Own Blood Cytokine)
can be determined.
Outlook
There
is surely still need of further research and development until
THE ULTIMATE CANCER MEDICINE has been found .
Until
then , the therapy with autologous target cytokines
( Own Blood Cytokine) probably offers the best and most helpful
starting point for a treatment in oncology. As far as the
use of endogenous blood is concerned, in 1993 the Deutsche
Krebshilfe have already recognized and published this (25).
Summary
The
differing and partly controversial interpretations for evaluation
the effects of cytokines that have caused the fundamental
differentiation between endogenous cytokines and recombinant
cytokines to be emphasized.
The
present thesis is intended as a practical guideline on how
colleagues can explain the principles of immunotherapy with
cytokines to the medical layman, e.g. in hospitals, official
authorities and authorities for financial aid , and the medical
service departments of he health insurance agencies (MDK),
and to describe the mentioned principles by means of a comparison
between the scientific features and the features in a form
in which they are generally understood by the public .
Literature
| 1. |
Abel,
U.: The cytostatic chemotherapy of advanced epithelial
tumors. A critical survey. Hippokrates Press Stuttgart
1990. |
| 2. |
Intensification
of toxic effects due to the combined administering of
5-
fluorouracil salts of the folinic acid. Instant information
on pharmaceutical preparations of Federal Institute for
pharmaceutical preparations and medicinal products, German
Med.Journ. 91, Vol. 31/32, August 1994(39) C-1383 |
| 3. |
Optimization
of therapies in Oncology ,2nd Expert discussion in the
clinic for cancer biology Freiburg, Clinic for cancer
biology Freiburg, 29. Marz 1996 |
| 4. |
Red
List 1995, List of pharmaceutical prepartions of BPI and
VFA,Publ.: Federal Assoc. of the pharmaceutical industry,
Frankfurt/Main, ECV
Editio Cantor, Aulendorf/Wurtt. |
| 5. |
Keilholz,
U., C. Scheibenbogen, W. Tilgen, L. Bergmann, E. Weidmann,
E.
Seither. M. Richter. B. Brado, S. Mitrou, W. Hunstein:
Interferon-
Interleukin-2 in the Treatment of Metastatic Melanoma.
Comparison of
two Phase II Trials, CANCER.Vol. 72, No. 2 July 15,1993 |
| 6. |
Arch
, R., K. Wirth, M. Hofmann, H. Ponta, S. Matzku, P. Herrlich,
M. Zoller: Participation in Normal Immune Responses of
a Metastasis-Inducing Splice Variant of CD44, Science,
31. July 1992,Volume 257, pp. 682-685 |
| 7. |
Klehr,
N.W.: The longterm culture of nucleated cellular components
of
peripheral blood in vitro. Akt. Dermatology 4,253-257(1978) |
| 8. |
Klehr,
N.W.,M.Janner, S. Bretz: Morphological examinations in
the
leucocyte-longterm culture. lst A new in vitro phenomenon
for the
diagnosis of the discoidal Lupus Erythematodes. Journ.
Skin Cancer
55(9)578-587(1980) |
| 9. |
Klehr,
N.W., S. Bretz, C. Pott: Morphological examinations in
the
leucocyte-longterm culture. 2nd A new detection method
for
proliferative tumor cells from peripheral blood. Journ.
Skin Cancer.
55(9)588-601(1980). |
| 10. |
K.
Panthel, J.R. lzbicki, M. Angstwurm, S. Braun, B. Passlick,
O. Karg, O. Thetter, and G. Riethmuller: Immunocytological
Detection of Bone Marrow Micrometastases in Operable Non-Small
Cell Lung Cancer, Cancer Research 53,1027-1031,March 1(1993) |
| 11. |
Pantel,
K., G. Schlimok, S. Braun. D. Kutter, F. Lindemann. G.
Schaller, I. Funke, J. R. Izbicki, G. Riethmuller: Differential
Espression of Proliferations-Associated Molecules in Individual
Micrometastatic Carcinoma Cells, Journ. Natl. Cancer Inst.
Vol. 85, No. 17, 1, |
| 12. |
Pantel,
K., G. Schlimok, M. Angstwurm, D. Weckermann, W. Schmaus,
H. Gath, B. Passlick, J.R. Izbicki, G. Riethmuller: Methodological
Analysis of lmmunocytochemical Screening for Disseminated
Ephitelial Tumor Cells in Bone Marrow. Journal of Hematotherapy
3:165-173(1994) |
| 13. |
Pantel
K.: Detection, monitoring and characterization of micrometastatic
carzinom cells: Implications for autologous stem cell
transplanation, Recent Advances in hematopoeitic stem
cell transplantation-clinical progress, new progress,
new technologies and gene therapie, University of California
, San Diego, School of Medicine. March 10-12, 1994, San
Diego ,Hilton Beach &Tennis Resort,California |
| 14. |
Osborne,
M.P., P.P. Rosen: Dectection and Management of Bone Marrow
Micrometastases in Breast Cancer, Onkology, August 1994 |
| 15. |
E.
Hansen, I. Frey, R. Knuchel-Clarke, J. Ruschoff, K. Taeger:
Tumor cells in surgical blood during tumor resection and
partial elimination by Ieucocyte filters. Haematology,
Munich, Sympomed,1994, vol 3, ppll6-122. |
| 16. |
Potter,
J.F., Longenbaugh G., Chu E., Dillon J., Rohmsdahl M.
Malmgren
A.: The relationship of tumor type and resectability to
the incidence of cancer cells in blood. Surg. Gyn. Obstet.
1960, 44:734-738 |
| 17. |
Tarin
D., J.E. Price, MGW, Kettlewell, R. G. of human tumor
metastasis studied in patients with peritoneovenous shunts,
Cancer Res. 1984, 44:3584-3592 |
| 18. |
Riethmuller
G.(1996): Genetic and immunological therapy of cancer,
facts and myths. Lecture Med. Assoc. Munich, Ludwig-Maximilian-University,
Munich, 29.2.1996 |
| 19. |
Kaufmann
M., Walter Joant, H. Maass, K. Passinger, D.K. Hossfeld:
Suggestions for therapy of female patients with metastasized
mammary carcinoma Germ. Med. Journ. 92, Vol. 33, 18. August
1995,(49)A-2189 |
| 20. |
Schirrmacher,
V. et al., Cancer Rev., 5, 19(1986) |
| 21. |
Riethmuller,
G.: Enc. for Oncologists: "Tumor-targeting"
in the case carcinoma of the colon. Munich 1995, Springer |
| 22. |
Mahl,
A., Nasif, W., Nechit, M., Klehr N.W., ATC-Specific signal
transduction in vitro: 9. Information Symp. on Endogenous
blood transfusion, March 1996 |
| 23. |
Wurfel,
W., M. Schleyer, Expert opinion of the Gynaecological
Clinic Wurzburg, on ATC-therapy,1992 |
| 24. |
Representative
treatment results in the case of different tumor diseases
Institute of Immunology und Cytobiology, Munich, Geiselgasteigstr.
120, 1990 |
| 25. |
Oncology
today:less relapses due to endogenous blood, German Soc.
for Cancer Aid Ēš 14, 1993.
|
|
|
|
